Latest Product Launch News

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Catapult Group International Ltd reported a milestone FY25 with ACV exceeding US$100 million, driven by strong SaaS growth and record profitability. The company’s innovative product launches and improved cost efficiencies underpin a confident outlook for FY26.

Merino & Co has amended its quarterly report to correct expenditure figures and clarify related party payments, while reporting significant operational progress including new product launches and cryptocurrency integration.

Elixinol Wellness Limited reported a robust FY24 performance, achieving an 81% increase in revenue and significantly narrowing its losses. The company is now focused on scaling its direct-to-consumer channels and operational efficiencies to reach profitability in 2025.

ECS Botanics is on track for a record-breaking FY25 harvest with a 50% production increase and new premium product launches, signaling strong growth and a positive cash flow outlook.

Xero Limited has reported a robust FY25 with 23% revenue growth and a Rule of 40 score exceeding 44%, underscoring its balanced approach to growth and profitability.

Aristocrat Leisure reported a robust first half FY2025 with 9% revenue growth and a 6% rise in normalised NPATA, driven by strategic acquisitions and market share gains. The company returned $533 million to shareholders while positioning for sustained growth across its gaming portfolio.

Humm Group reported a solid 10% increase in assets under management to $5.3 billion for 3Q25, maintaining stable margins while advancing a new hybrid loan product and IT platform modernization.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Universal Biosensors reported a 6% increase in revenue for Q1 2025 but posted a net loss of A$3.84 million, with cash reserves sufficient only through Q3 2025, raising questions about its financial sustainability.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.